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Available online 9 December 2015The neo-epitope tTg (tTg-neo) autoantibody, never challenged the anti-tissue transglutaminase (tTg) premier-
ship, recommended by ESPGHAN, for celiac disease (CD) diagnosis.
Pediatric CD (PCD), abdominal pains and normal children, normal adults, and rheumatoid arthritis patients, were
tested using the following ELISAs detecting IgA, IgG or both IgA and IgG (check): AESKULISA® tTg (tTg; RUO) and
AESKULISA® tTg-neo.
HigherODactivitywas detected for tTg-neo IgA, IgG and IgA+ IgG than for tTg. tTg-neo IgA, IgG correlated better
with intestinal damage than tTg. The tTg-neo combined IgA+ IgG ELISA kit had higher sensitivity and a compa-
rable speciﬁcity for the diagnosis of PCD. The drop in the % competition was much higher with the tTg-neo then
the tTg antibodies. The false positivity of the tTg was signiﬁcantly higher than the tTg-neo one.
Serological diagnostic performances, reﬂection of intestinal damage, diverse epitopes and false positivity were
better with the tTg-neo.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
Celiac disease
Tissue transglutaminase
Neo-epitope tTg
Antibodies
Autoantibodies
Serological markers1. Introduction
Celiac disease (CD) is an autoimmune inﬂammatory disorder of the
small intestine, triggered by the ingestion of prolamins contained in
wheat, barley, rye or oat, in genetically susceptible individuals. The general
accepted incidence in the western countries is 1–1.5%. However, in high
risk populations, the average risk of CD can reach 5–10% (Lerner, 2014).
There is an increased risk of complications such as hematological
and gastrointestinal malignancies, osteoporosis/penia and many other
extraintestinal manifestations, decreased height, malnutrition and nu-
tritional deﬁciencies, fertility impairment, stillbirth, dismaturity, psy-
chosocial retardation, impairment of quality of life, increased mortality
and additional autoimmune conditions, if left untreated. Each year of
delay in CD detection is associatedwith a signiﬁcant increase inmedical
care costs. Its correct diagnosis and early gluten free diet implementa-
tion, can lead to considerable decrease in morbidity, mortality, and im-
proved efﬁciencies in both economic and medical resources (Picarelli
et al., 2014). The epidemiology and phenotype of CD are constantlytTg complexed to gliadin; PCD,
l children; NA, normal adults;
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. This is an open access article underchanging. It has been shown that the classic intestinal clinical picture
of malnutrition, chronic diarrhea and nutritional deﬁciencies are
disappearing and extraintestinal presentations are emerging. Skin, en-
docrine, skeletal, hepatic, hematological, thrombophylic, gynecological,
fertility, dental and behavioral abnormalities are often described. Now-
adays, we are witnessing an epidemiological shift in the disease pheno-
type toward a more advanced age, and increased prevalence of latent,
hyposymptomatic or asymptomatic behavior (Lerner, 2014; Lerner
et al., 2013). All these changes make the diagnosis of the disease more
difﬁcult and the reliance on symptomatology more remote (Katz et al.,
2011; Lerner, 2014). These are some of the reasons why serological
screening and diagnosis of CD have achieved prime importance.
The newguidelines of the European Society of Pediatric Gastroenter-
ology, Hepatology and Nutrition (ESPGHAN) for the diagnosis of pediat-
ric celiac disease (PCD) rely on anti-human tissue transglutaminase
(tTg) as the prime and unique antibody for screening of the suspected
PCD population (Husby et al., 2012). Despite the extended CD associat-
ed serological repertoire, none of the tests has challenged tTg premier-
ship (Lerner, 2014). tTg complexed to gliadin represents neo-epitopes
resulting from the enzyme–substrate interaction and antibodies against
the complex are called tTg neo-epitope (tTg-neo). Fig. 1 describes
schematically, the pathway of the ingested gluten leading to post-
translational modiﬁcation of the gliadin docked on either tTg that
deamidates the gliadin peptide (Fig. 1A) or the tTg–neo that cross
links the gliadin peptides (Fig. 1B). There are three possibilities for auto-
antibody production: 1. Anti tTg, 2. Anti deamidated gliadin peptide,the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. The tTg enzymatic-gliadin relationship: A. Gliadin deamidation or cross-linked by the tTg enzyme. B. The tTg docked by gliadin complex and the antibodies produced to its different
epitopes.
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linked to the gliadin peptides. This cross linking induces chemical, phys-
ical and three dimensional conﬁgured modiﬁcations that unravels or
creates neo-epitopes on the complex.
Since head to head comparison between tTg and tTg-neo autoanti-
bodies are scarce, we undertook the challenge to compare the two, in
relation to diagnostic reliability, reﬂection of intestinal damage and se-
rological laboratory performance in pediatric CD (Rozenberg et al.,
2011; Rozenberg et al., 2012). All the aspects examined presently
show that tTg-neo is distinguished from tTg, as are their corresponding
autoantigens. More so, data are presented showing that the tTg-neo au-
toantibody effectiveness outperforms the tTg ones in diagnosing CD.
2. Material and methods
2.1. Patient populations
Five different groups of patients were investigated:
1. 95 pediatric CD patients (CD),mean age 8.3±4.4 years, F/M 1:0.9. The
CDgroupwasdivided according to thedegree of intestinal injury, using
Marsh criteria, to 6 groups M0, M1, M2, and M3a–c. M0 represents a
normal intestinal biopsy and M3c total villous atrophy (Rozenberg
et al., 2012). These sub-groups contained 34, 11, 13, 41, 27, 7 children,
respectively. Only M2 and above was considered to be CD.
2. 45 childrenwith abdominal pain, having gastroscopies for evaluation
of their symptoms (AP), mean age 7.3 ± 5.1 years, F\M 1:0.9 respec-
tively, served as a normal gastrointestinal, symptomatic control
group having M0 or M1 intestinal morphology.
3. 99 normal children (NC) mean age 8.5 ± 4.2 years F/M 1:0.96, re-
spectively, served as a normal gastrointestinal asymptomatic control
group.
4. 79 normal adults (NA) mean age 28.1 ± 5.1 years, F/M 1:0.7, respec-
tively, comprised the fourth group. The adults were healthy blood
donors and served as a normal asymptomatic control group.
5. 135 RA adult patients from the ADAPTHERA study cohort, where
blood was drawn at a very early stage of RA and at 3 follow up
time points, were analyzed as a non-celiac autoimmune disease,
pathological control group. ADAPTHERA is a network to improve pa-
tient care and toﬁndnewbiomarkers for thediagnosis and prognosis
of RA. Mean age 55 ± 12.7 years F/M 1:0.2, respectively.
Only groups 1 and 2 underwent esophago-gastro-duodenoscopy
using a GIF-xp 20 endoscope (pentax, Tokyo, Japan). At least 5biopsies/patient were obtained: 4 from the second part of the duode-
num for the diagnosis or exclusion of CD and 1 from the antrum. The bi-
opsies were immediately ﬁxed in buffered formalin and embedded on
edge in parafﬁn. Sections were stained with hematoxylin–eosin and
Giemsa, analyzed by a pathologist and graded according to Marsh
criteria, as previously described (Rozenberg et al., 2011).
Celiac disease was diagnosed according to the revised criteria of the
European Society for Pediatric Gastroenterology and nutrition, based on
speciﬁc serology (anti tissue transglutaminase antibodies, by ELISA) and
duodenal biopsies (Husby et al., 2012). All the participants were on a
gluten containing diet and had a physical examination, laboratory
work-up, celiac serology and endoscopy. On the day of endoscopy
5 ml of peripheral blood was withdrawn, centrifuged at 5000 c/s for
10 min and the serum was frozen in−80 °C until assayed for serology.
The local ethical committee approved the study and the participants or
legal guardians signed an informed consent.
The sera of the CD and AP groups were collected in Carmel Medical
Center, Haifa, Israel, during 2010–12.When symptomatic, the range pe-
riod of symptomswas 2 month to 1.5 years. The sera for groups 3 and 4
were an in-house bio-bank and were acquired commercially from in.-
vent DIAGNOSTICA GmbH, Germany.
In the ﬁfth study cohort, RA was diagnosed by a rheumatologist at a
disease duration b6 months. The study was performed in cooperation
with the Johannes Gutenberg University of Mainz, department of Inter-
nal Medicine, Division of Rheumatology and Clinical Immunology with
local ethical committee approval and the participants or legal guardians
signed an informed consent. The patients were treatment naive on the
ﬁrst visit, but were pharmacologically treated on the following visits.
3. Antibodies determinations
3.1. ELISA
Sera were tested for anti-tTg and anti tTg-neo antibodies using
solid phase enzyme immunoassays (AESKULISA, AESKU.DIAGNOSTICS
(AESKU.Kipp Institute, Wendelsheim, Germany), according to the
manufacturer's protocol.
Brieﬂy, serum samples were diluted 1:101 and incubated inmicroti-
ter plates coated with the speciﬁc antigen on the solid phase. Binding
was detected by antihuman immunoglobulins peroxidase (conjugate)
and 3,3′,5,5′-Tetramethylbenzidine-substrate (Seramun Diagnostica
GmbH, Germany). The sera were considered positive for antibodies
when assessed according to the manufacture's equation for cut-off
value determination.
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tTg (tTg; RUO) and AESKULISA® tTg New Generation (Neo-epitope tTg
complexed to gliadin) were used to measure the antibody proﬁle of
the different study cohorts.
The anti-tTg-neo-epitope ELISA is a solid phase enzyme immunoas-
say for the quantitative and qualitative detection of IgA, IgG or IgA and
IgG (check) combined antibodies against neo-epitopes of tTg crosslinked
with gliadin speciﬁc peptides. Positive cut-off was N18 U/ml. The anti-
tTg (RUO) ELISA is coated with highly puriﬁed tTg for the combined
quantitative and qualitative detection of IgA, IgG or IgA and IgG
(check) in the sera. Positive cut-off was N18 U/ml
3.2. Competition study
Competition ELISAwas used to testwhether the two single antigenic
component (tTg and tTg-neo) inﬂuence the immunoreactivity of the
patients' sera in an ELISA experiment. The aim is being to look for
cross reactivity between the single isolated tTg and the formed tTg-
neo-epitope complex.
Sera were selected according to their antibody activities as deter-
mined by their corresponding ELISAs.
As an internal control, sera which showed positive results in the
tTg-neo (IgA or IgG) assay from AESKU, but negative results to the
self-performed tTg (RUO) were used. These selected sera should not
show competition to the single competitor tTg, but, high competition
to the tTg- neo-epitope.
4. Statistics
Scatter diagrams and regression analysis comparing the 6 antibod-
ies' OD activities to the degrees of the intestinal damage were used.
Mean values of optical density (immunoreactivity against different an-
tigens in patient sera) at different Marsh degrees were comparedFig. 2. The immunoreactivity of CDpatients (U/ml) in six different assays: anti-tTg (RUO) and an
higher OD activity was detected for tTg neo IgA, IgG and IgA + IgG than for tTg (p b 0.001, p busing the t-test and a p b 0.05 was deﬁned statistically signiﬁcant. For
analysis and graphical presentation, the statistical software MedCalc
Version 12.7.1.0 was used. Sensitivity, speciﬁcity and the Area Under
the Curve (AUC) values were calculated.
The third and fourth groups' antibody determination data were
included in the statistical workup of the antibody performance
comparisons.5. Results
A signiﬁcantly higher OD activity was detected for tTg-neo IgA,
IgG and check than for the corresponding tTg isotypes (p b 0.0001,
p b 0.0001, p b 0.001, respectively) (Fig. 2).
Comparing antibody activity as a reﬂection of intestinal damage, tTg-
neo IgA, IgG and check antibodies, correlated better with the degree of
the intestinal atrophy than tTg antibodies(r2 = 0.9567, 0.9577, 0.9464
compared to 0.9254, 0.4452,0.9291 (p = 0.0023, p b 0.0001 and
p = 0.1162), respectively) (Fig. 3a,b,c).
Analyzing the graphs of Figure No 3, it is clear that IgA and IgG
isotypes of tTg-neo performed better. The comparison of the check
isotypes did not reach statistical signiﬁcance (Fig. 3c). A sequential
isotype hierarchy is seen: The IgA (and the combined check), better
reﬂect intestinal damage then the IgG isotype. The differential gapes,
between the 2 autoantibodies, climbing along the increased Marsh
criteria, is accentuated mainly in the IgA isotype and to a lesser degree
in the check isotypes graphs.
Calculating sensitivities, speciﬁcities, positive and negative predict-
ed values and AUC, the tTg-neo had signiﬁcantly better parameters, in
IgA, IgG and check isotypes however the check isotypes exhibited the
best performance, compared to the tTg isotypes, respectively, as
shown in Table 1.
In view of the difference between tTg-neo and tTg autoantibodies
in activity, intestinal damage reﬂection and clinical serologicalti-tTg neo-epitope IgA and IgG separately and as a check ELISA, are exposed. A signiﬁcantly
0.001 and p b 0.001, respectively).
Fig. 3. The correlation between antibodies activities and the degree of the intestinal damage: A. IgA-tTg and IgA-neo-tTg. B. IgG-tTg and IgG-neo-tTg. C. tTg and neo-tTg checks (IgA+ IgG).
18 A. Lerner et al. / Journal of Immunological Methods 429 (2016) 15–20performance, an adsorption study to explore similarities or differences
in their antigenic epitopes was conducted. As shown in Fig. 4, their indi-
vidual competition curves are diverse. The positive patients' sera react
differently along the increased antigen concentrations in the ELISA
wells. The drop in the % competition was much higher with the tTg-
neo than the tTg antibodies, indicating that antibodies recognizing
tTg-neo recognize epitopes additional to those present or accessible in
uncomplexed tTg enzyme.
To date, the assays have been performed on CD patients and normal
controls. To further clarify the unique identity of the tTg-neo and to ex-
plore its different behavior from the tTg autoantibodies, their activities
were checked in a different autoimmune disease, namely RA. As
shown in Fig. 5, in the naive RA patient, on the ﬁrst visit after diagnosis
and along the evolution of the disease under pharmaceutical therapy,
the two autoantibodies behave differently. The % positivity of tTg anti-
bodies was signiﬁcantly higher than tTg-neo antibodies, along all the
visits (visit 1, 2, 3, 4, p b 0.05 respectively). Determination of CD associ-
ated autoantibodies in the RA group, reveals that tTg is less speciﬁc forTable 1
The serological performances of IgA, IgG and check isotypes of tTg-neo in comparison to
tTg in pediatric celiac disease.
Antibodies Sensitivity Speciﬁcity AUC p Marsh
correlation
(r2)
tTg IgA 55.6 100 0.937 b0.0001 0.9254
tTg IgG 11.1 100 0.894 b0.0001 0.4452
tTg check 77.8 100 0.971 b0.0001 0.9291
tTg neo-epitope IgA 84.9 99.0 0.985 b0.0001 0.9567
tTg neo-epitope IgG 75.8 98.0 0.970 b0.0001 0.9577
tTg neo-epitope check 97.0 99.0 1.0 b0.0001 0.9464CD, mirrored by it higher false positivity, in relation to the lower false
positivity of its competitor, in RA patients' sera.
6. Discussion
At the beginning of 2012 the ESPGHAN released a new set of guide-
lines for the diagnosis of CD, based on both the signiﬁcant progress in
the development of speciﬁc antibody tests and on the understanding
of the high prevalence of speciﬁc HLA haplotypes in CD (Husby et al.,
2012). These advances were the basis of the updated guidelines for CD
diagnosis in symptomatic and asymptomatic individuals, where in cer-
tain circumstances, small bowel biopsy can be omitted. The new guide-
lines recommended screening of suspected individualswith IgA-tTg and
according to the levels to continue the ﬂow chart by multiple possible
avenues.
Screening the available pediatric literature, the sensitivity/speciﬁcity
of tTg-IgA is ≥90 (74–100)/≥90 (78–100), respectively (Giersiepen,
2012; Gujral et al., 2012; Lewis & Scott, 2010). While the performances
of the tTg-neo are: sensitivity/speciﬁcity 98–100/93–96.2, respectively
(Barak et al., 2013; Bizzaro et al., 2012; Lerner, 2014; Rozenberg et al.,
2011; Rozenberg et al., 2012; Tozzoli et al., 2010).
Based on the performance of the two serological kits, tTg-IgA and
tTg-neo antibodies were compared, back to back, on a well character-
ized pediatric celiac patient population, at a single laboratory site, by a
single laboratory technician to reduce variability and increase homoge-
neity of the assays.
The results show that the tTg-neo, which combine IgA + IgG
antibodies against the tTg docked gliadin complex have the following
advantages over the tTg-IgA antibodies, recommended by ESPGHAN:
1. Higher OD activity. 2. A better reﬂection of the intestinal pathology.
3. Higher sensitivity, though comparable speciﬁcity. 4. A better area
under the curve. 5. Being a combined antibody, checking additionally
Fig. 4. Adsorptive study comparing celiac disease tTg to neo-tTg autoantibodies competing on the corresponding antigenic epitopes.
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on competition assays, it is directed against different/additional epi-
topes compared to its competitor, the tTg antibody. 7. It is more speciﬁc
for CD detection, since higher false positivity of IgA-tTg was detected in
RA patients.
Several other studies have observed the good performance of the
tTg-neo and the present study substantiates and extends these results
to some additional aspects (Barak et al., 2013; Husby et al., 2012; Katz
et al., 2011; Lerner et al., 2015a; Lerner et al., 2013; Lewis & Scott,
2010; Lytton et al., 2013; Matthias, 2010; Matthias et al., 2011;
Picarelli et al., 2014; Porcelli et al., 2014; Remes-Troche et al., 2006;
Remes-Troche et al., 2008). Recently, anti-neo-epitope tTg antibodies
were shown to represent a new and sensitive serological marker of der-
matitis herpetiformis, a disease closely related to CD (Lytton et al.,
2013).More so,when checked, it seems that the neo-tTg antibodies pre-
cede the appearance of tTg antibodies and thus have also a potential
predictive value (Bizzaro et al., 2012; Porcelli et al., 2014). Most recent-
ly, multiple false positive and false negative situations and reasons haveFig. 5. tTg and neo-tTg check antibodies performance on the ﬁrst visit and follow-up visits of th
follow up doctor visit 4. Symbols in red show the outliers in antibody determination of each pbeen described for IgA-tTg (Lerner et al., 2015b), indicating the com-
plexity of its titer interpretation, outside the normal limits, and in the
gray diagnostic zone.
The differences in reduction in the % competition between the two
autoantibodies, indirectly leads to the conclusion that the two autoanti-
bodies do not recognize the same antigenic epitopes and they are di-
rected to different structures along the tTg enzyme or its enzymatic
complex docked by gliadin. The most recent publication shade ad-
ditional light on the cross-linked gliadin–tTg complex (Di Pisa et al.,
2015). Results showed that cross-linking is determinant to assume
conformations, which are not accessible to the linear fragments.
At the end of the day, clinicians who must diagnose and deal with
high-risk or symptomatic patients, regardless of their genetic risks and
disease triggers, constantly seek biomarkers that can identify or rule
out, follow or predict CD. They are overwhelmed with a plethora of
markers and extensive heterogeneous literature. The present study dis-
cusses an additional CD biomarker that challenges the premier choice of
anti tTg, recommended by CD societies.e RA patients (Symbol Legend: doctor visit 1, doctor visit 2, doctor visit 3 and
atient sample set at the different doctor visits, respectively.
20 A. Lerner et al. / Journal of Immunological Methods 429 (2016) 15–20It is hoped that additional studies will compare, head to head, other
CD associated autoantibodies, thus challenging the tTg-IgA recom-
mended ﬁrst and only choice. The present study highlightsmultiple dif-
ferences between IgA-tTg and the neo-tTg antibodies concerning
childhoodCD. It can be concluded that the tTg autoantigen is completely
different from the complex of tTg docked by gliadin peptide, since the
neo-tTg antibody is directed against speciﬁc epitope(s) not detected
by IgA-tTg. Their corresponding speciﬁc autoantibodies are similarly
different in clinical serological diagnostic performances, small bowel pa-
thology reﬂection, targeted epitopes, coverage of IgA deﬁciency and
false positivity in other autoimmune conditions. It is suggested that
the future revision of ESPGHAN criteria and other CD professional
guidelines, should consider embedding tTg-neo in the recommended
diagnostic ﬂow chart of CD detection, diagnosis and follow-up.
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